Anavex Life SciencesAVXL +7.39%30 Buyback Yield % is -14.20 as of Jul. 04, 2026. GuruFocus rates AVXL with a GF Score™ of 30/100. The stock has 1 warning sign investors should review. Among 744 Biotechnology companies, Anavex Life Sciences ranks worse than 59.01% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
Anavex Life Sciences Buyback Yield % Related Terms
Anavex Life Sciences Buyback Yield % Historical Data
* Premium members only.
The historical data trend for Anavex Life Sciences's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVXL vs SLGL, FATE, FHTX: Buyback Yield % Comparison
For the Biotechnology subindustry, Anavex Life Sciences's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anavex Life Sciences Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anavex Life Sciences's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Anavex Life Sciences's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anavex Life Sciences (AVXL) has a Buyback Yield % of -14.20 as of Jul. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Anavex Life Sciences and its competitors. According to the industry distribution chart, Anavex Life Sciences ranks #439 out of 744 companies in the Biotechnology industry, placing it in the top 59%.
Is Anavex Life Sciences' Buyback Yield % too high?
Anavex Life Sciences' current Buyback Yield % is -14.20. Based on the distribution chart, Anavex Life Sciences ranks #439 out of 744 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Anavex Life Sciences has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Anavex Life Sciences' Buyback Yield % compare to SLGL and FATE?
According to the Biotechnology industry distribution chart, Anavex Life Sciences ranks #439 out of 744 companies for Buyback Yield %. This places Anavex Life Sciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Anavex Life Sciences and its competitors. Anavex Life Sciences's current Buyback Yield % is -14.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anavex Life Sciences stock overvalued right now?
Anavex Life Sciences (AVXL) has a current Buyback Yield % of -14.20. The current Buyback Yield % is -14.20. Anavex Life Sciences' overall GF Score™ is 30/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Anavex Life Sciences (AVXL), the current Buyback Yield % is -14.20 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.
30GF Score
Get the complete analysis for AVXL
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVXL has been successfully added to your 
